

Genome editing in animals with minimal PAM CRISPR-Cas9 enzymes

Jeremy Vicencio^{1#}, Carlos Sánchez-Bolaños^{2,3#}, Ismael Moreno-Sánchez^{2,3}, David Brena¹, Dmytro Kukhtar¹, Miguel Ruiz-López¹, Mariona Cots-Ponjoan¹, Charles E. Vejnar⁴, Alejandro Rubio^{2,3}, Natalia Rodrigo Melero⁵, Carlo Carolis⁵, Antonio J. Pérez-Pulido^{2,3}, Antonio J. Giráldez^{4,6,7}, Benjamin P. Kleinstiver^{8,9,10}, Julián Cerón^{1*}, Miguel A. Moreno-Mateos^{2,3*}

1 Modeling human diseases in *C. elegans* Group, Genes, Disease and Therapy Program, Bellvitge Biomedical Research Institute—IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

2 Andalusian Center for Developmental Biology (CABD), Pablo de Olavide University/CSIC/Junta de Andalucía, Ctra. Utrera Km.1, 41013, Seville, Spain.

3 Department of Molecular Biology and Biochemical Engineering, Pablo de Olavide University, Ctra. Utrera Km.1, 41013, Seville, Spain.

4 Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510, USA

5 Center for Genomic Regulation (CRG), Barcelona, 08003, Spain

6 Yale Stem Cell Center, Yale University School of Medicine, New Haven, CT, 06510, USA

7 Yale Cancer Center, Yale University School of Medicine, New Haven, CT, 06510, USA

8 Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA

9 Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA

10 Department of Pathology, Harvard Medical School, Boston, MA 02115, USA

#Equal contribution *Corresponding Authors

Running title: Minimal PAM genome editing in animals

ABSTRACT

The requirement for Cas nucleases to recognize a specific PAM is a major restriction for genome editing. SpCas9 variants SpG and SpRY, recognizing NGN and NRN PAM, respectively, have contributed to increase the number of editable genomic sites in cell cultures and plants. However, their use has not been demonstrated in animals.

We have characterized and optimized the activity of SpG and SpRY in zebrafish and *C. elegans*. Delivered as mRNA-gRNA or ribonucleoprotein (RNP) complexes, SpG and SpRY were able to induce mutations *in vivo*, albeit at a lower rate than SpCas9 in equivalent formulations. This lower activity was overcome by optimizing mRNA-gRNA or RNP concentration, leading to efficient mutagenesis at regions inaccessible to SpCas9. We also found that the CRISPRscan algorithm can predict SpG and SpRY activity *in vivo*. Finally, we applied SpG and SpRY to generate knock-ins by homology-directed repair. Altogether, our results expand the CRISPR-Cas targeting genomic landscape in animals.

INTRODUCTION

CRISPR-Cas technology has become a revolution in molecular biology, biotechnology, and biomedicine¹. However, the requirement for a Cas-specific protospacer adjacent motif (PAM) prohibits targeting many genomic regions. The inability to target freely within a genome limits the selection of the most optimal targets for precision genome editing. This is particularly critical when targeting and editing short regions in the genome such as miRNA loci or targets, transcription factors binding sites, enhancers, or promoters. The distance from the cut site or PAM to the edit is also essential for generating the desired mutation by homology direct repair (HDR)² or base editing, respectively³. To alleviate this handicap, newly discovered or engineered Cas proteins have increased the number of targets with different or more flexible PAMs⁴⁻¹¹. In particular, SpG and SpRY are two modified versions of SpCas9 with more relaxed PAM requirements than NGG and, consequently, can target a greater fraction of the genome (**Supplementary Fig. 1a,b**). Specifically, SpG showed high activity in targets with NGN PAMs whereas SpRY could target nearly every sequence in the genome, with targets harboring NRN (R = A or G) PAMs being more efficiently edited than those with NYN (Y = C or T) PAMs⁶. However, most of the new or modified Cas nucleases, including SpG and SpRY, are first optimized and examined in mammalian cell culture without validation in animal models.

Here, we characterize and optimize SpG and SpRY, in two different animal models widely used in biology and biomedical research: zebrafish (*Danio rerio*) and nematodes (*Caenorhabditis elegans*). We show that purified proteins or mRNAs coding for SpG or SpRY under optimized conditions determined in this study can efficiently target and edit DNA at different loci upon injection in zebrafish embryos and *C. elegans* germlines¹². In addition, we show that the *in vivo* prediction algorithm CRISPRscan¹³ can discriminate between highly active and inefficient gRNAs for SpG and SpRY, facilitating the use of these nucleases *in vivo*. Finally, we provide a *C. elegans* strain that endogenously expresses SpG, thus simplifying genome editing in this animal model. Altogether, our results expand the CRISPR-Cas toolbox in vertebrate and invertebrate animals and set a baseline for the use of novel SpCas9 variants in other animal models.

RESULTS

Optimization of SpG and SpRY for editing zebrafish and *C. elegans* genomes

We assessed the activities of SpG and SpRY in animals by testing them in two distinct model organisms, zebrafish and *C. elegans*. To compare the activity of different nucleases *in vivo*, we injected one-cell stage zebrafish embryos using mRNAs coding for SpCas9 (WT), SpG, and SpRY targeting two sites with NGG PAMs in the gene *slc45a2* (*albino*), previously analyzed for SpCas9¹³ (**Fig. 1a**). The lack of function of *slc45a2* is observed as a loss or reduction in pigmentation that can be quantified (**Fig. 1b,c,d**)¹³. While we were able to recapitulate the phenotypes induced from one high efficiency gRNA and another that exhibits medium to poor efficiency¹³, experiments with SpG and SpRY revealed lower levels of editing on NGG PAM at standard concentrations for gRNAs and Cas9 mRNA (**Fig. 1c**), similar to as previously reported in human cells⁶. We hypothesized that this lower activity with SpG and SpRY in our experiments might result from suboptimal concentrations of gRNA and Cas9 mRNA injected in zebrafish embryos. Thus, by increasing the concentration of mRNA and/or gRNA, we observed a significant enhancement in activity as evidenced by higher penetrant phenotypes for both gRNAs (**Fig. 1d**). Such increase did not affect embryonic viability, suggesting a lack of toxicity-associated effects (**Fig. 1d, Supplementary Fig. 2a,b,c**). Interestingly, increasing the amount of mRNA and gRNA per embryo also improved SpCas9 activity but to a lesser extent than SpG and SpRY for the more efficient gRNA (**Supplementary Fig. 2b,c**).

In parallel, we tested SpG and SpRY in *C. elegans* via RNP delivery since it has been shown to be more efficient than plasmid-based delivery and it limits the period of Cas activity^{14,15}. We purified wild-type SpCas9, SpG, and SpRY for performing *in vitro* and *in vivo* experiments (**Fig. 1e**). Since the activity of Cas9 orthologs found in diverse microbes varies with temperature⁷, we examined whether the activity of the engineered SpG and SpRY variants displayed temperature sensitivity that would hamper their use in other organisms growing at temperatures below 37 °C such as zebrafish and *C. elegans*. We tested these

proteins *in vitro* at different temperatures including 15, 25, 37, and 50 °C. All three purified proteins, along with a commercially obtained wild-type Cas9 protein, generated targeted DNA double-strand breaks on a substrate harboring an NGG PAM with similar efficiency (**Supplementary Fig. 3**). To analyze the specificity of these proteins, we investigated their sensitivity to mismatches located in the protospacer sequence. Remarkably, SpG and SpRY were similarly sensitive to mismatches proximal to the PAM (position +1 and +5) at 25 or 37 °C (**Fig. 1f**). Then, we validated the tolerance to mismatches *in vivo* by scoring a dominant phenotype caused by *dpy-10* targeting, by using SpG with the matched guide and a guide with a mismatch at position +5 (**Fig. 1g**). We observed that a single mismatch almost completely abolished the *in vivo* activity of SpG, and therefore, the amino acid substitutions in this variant do not lead to relaxed recognition of the protospacer sequence relative to SpCas9, which is important for maintaining specificity. Then, we further tested their activities *in vivo* at two different sites with NGG PAMs.

Dominant mutations of the *C. elegans* gene *dpy-10* produce an overt phenotype (dumpy or roller animals) in the F₁ generation that we use for scoring CRISPR-Cas activity. In particular, there is an efficient NGG gRNA for *dpy-10* that is commonly used as a co-CRISPR control for effective microinjections ^{16,17}. However, other *dpy-10* alleles are recessive, producing a phenotype in the F₂ generation instead (**Supplementary Fig. 2d**). We first used the standard gRNA and ssDNA repair template (to generate the *cn64* allele) for *dpy-10* as in co-CRISPR assays and found that SpCas9 was more efficient than SpG and SpRY in producing *dpy-10* mutations with an NGG PAM (**Supplementary Fig. 2e**). Since the half-life of these nucleases is limited, we scored their efficiency at two different periods and observed that it was lower after 24 hours (**Supplementary Fig. 2e**).

We targeted an additional locus to confirm the gradient of efficiency SpCas9 > SpG > SpRY on NGG PAMs. By scoring the absence of fluorescence in the F₂ of animals with the endogenous reporter *gtbp-1::wrnScarlet*, we evaluated the efficiency of these three nucleases (**Fig. 1h**). This experiment corroborated the gradient of activity among the distinct Cas nucleases targeting an NGG PAM, with SpCas9 again having the highest efficiency, and SpRY the

least (**Fig. 1i**). To control microinjection quality, we also used the *dpy-10* co-CRISPR strategy.

In a previous study, we found that Cas9 concentrations can be raised six-fold without any apparent toxicity¹⁸. Thus, when we used SpG at a six-fold higher concentration (8μM in the injection mix) we observed an efficiency of wrmScarlet targeting similar to that of SpCas9 (**Fig. 1i**).

Altogether, we demonstrate that SpG and SpRY, when using optimized delivery concentrations of mRNA or purified protein formulations, can exhibit high editing activities in animals grown at different temperatures. Furthermore, SpG and SpRY are equally sensitive to mismatches in the protospacer sequence as compared to SpCas9.

Genome editing with SpG and SpRY across various zebrafish target sites

To further evaluate SpG activity *in vivo*, we selected 15 targets with NGH (H = A, C, or T) PAM in three genes whose loss-of-function (**Fig. 2a**) can be easily quantified by phenotype and correlates with the efficiency of different CRISPR-Cas systems^{13,19}. As we previously optimized for targeting sites with NGG PAMs, we observed a strong enhancement of activity in most of the targets when increasing gRNA and mRNA concentrations (**Supplementary Fig. 4a,b,c**). Notably, using our optimized conditions, we found high-efficiency activity in 6 out of 15 analyzed targets where at least 50% of the embryos presented severe (Class II or alb/gol severe mosaic) or extremely severe (Class III or alb/gol like) phenotypes, and 12 out of 15 showed some activity (at least 10% of embryos are mosaic mutants) (**Fig. 2b,c,d**). These efficiency ratios were comparable to what was observed with WT SpCas9 in similar experiments¹³. In addition, by amplifying the genomic target regions from some of these mosaic mutant embryos, we identified DNA lesions induced by SpG activity that were similar to what is described for SpCas9 with short insertions or deletions (**Supplementary Fig. 5a**).

SpRY was previously shown to edit targets with NRN PAM sequences, but those with NGG and NGH PAMs can be efficiently edited with SpCas9 and SpG, respectively. Therefore, we focused our analysis of SpRY against eight genomic targets with NAN PAMs from the three loci that we previously used for SpG. Using

our optimized conditions, we observed variable activity at the different targets where 3 out of 8 showed high activity (**Fig. 2e,f, Supplementary Fig. 6a,b,c**), and 6 out of 8 showed some activity. Importantly, injections with SpCas9 mRNA showed very low penetrance or absence of phenotypes in the NGH or NAN targets (at least more than 90% WT embryos at the phenotype level) where SpG and SpRY performed efficiently, respectively (**Supplementary Fig. 6d**). This result reinforces the observations in mammalian cells where SpCas9 activity against targets with non-NGG PAMs is generally low or absent^{6,20}. Altogether, our results demonstrate that SpG and SpRY can efficiently generate mutants in zebrafish embryos at genomic sites where SpCas9 is poorly active or inactive, with variable activity among different targets.

Comparison of SpCas9, SpG, and SpRY across various targets *in C. elegans*

C. elegans is a model organism with convenient features for testing new Cas proteins *in vivo*²¹. We evaluated SpG and SpRY activities on NGH and NAN PAMs, respectively, for targeting *gtbp-1:wrmscarlet* (**Fig. 3a**). First, we checked whether RNP concentration is also critical for editing with SpG on a site with an NGH PAM. As has occurred at NGG PAM targets, SpG is more efficient when the concentration is increased from 1.3 to 3.7, and to 8.0 μ M (**Fig. 3b**). By injecting six-fold higher (300 mM) KCl concentration in a CRISPR-SpG experiment targeting an NGH PAM while keeping the nuclease concentration constant, we observed that the higher salt concentrations in the injection mix does not affect editing efficiency (**Supplementary Fig. 7**).

To compare the efficiency of SpCas9 and SpG for targeting sites with NGH PAMs, we performed experiments using these nucleases at the highest concentration (8 μ M) to produce mutations in *gtbp-1:wrmscarlet*. We observed that SpG was more efficient than SpCas9 (mean of 62.1% vs 30.2%) when targeting sites with NGH PAMs (**Fig. 3c**). Interestingly, as previously reported in human cell lines⁶, we found that SpRY is also efficient in targets with an NGH PAM *in vivo*, with similar activity to that of SpG (**Fig. 3c**). On the contrary, SpG was previously reported to exhibit minimal activity against sites with NAN PAMs in human⁶. Therefore, we focused on the analysis of SpRY activity in three

different NAN targets in the *gtbp-1:wrnScarlet* locus. First, we studied the *in vitro* capacity of SpCas9, SpG, and SpRY to cleave dsDNA targets with NAN PAMs. *In vitro*, SpRY had the highest cutting efficiency at all three target sites harboring an NAC PAM (**Fig. 3d**). As expected, SpG was also capable of efficiently cutting two of the targets *in vitro*. This may be due to the minor but still detectable SpG activity as previously observed at NAC sites in mammalian cells⁶ (**Fig. 3d**). When tested *in vivo*, as we observed for SpG, higher concentrations of SpRY RNP significantly enhanced its activity in one of the analyzed targets (**Fig. 3e**). Finally, we compared the efficiency of SpRY and SpCas9 in one of the targets with a high level of mutagenesis (NAN 2) and demonstrated that SpRY is much more effective than SpCas9 for editing NAN PAMs *in vivo* (**Fig. 3e**).

Together, these results are consistent with those obtained in zebrafish mRNA-injected embryos and suggest that increasing the concentration of SpG and SpRY RNPs enhances the activity of these nucleases in *C. elegans*, particularly in NRN targets where SpCas9 has minimal activity. Furthermore, similar to our observation in zebrafish, the DSBs produced by SpG and SpRY lead to the formation of indels near the cut site, analogously to SpCas9 (**Supplementary Fig. 5b**), and each target site had variable activity that likely depends on the genomic target site and nucleotide context adjacent to the PAM as described for Cas9 in different models^{6,13,22,23}.

CRISPRscan predicts SpG and SpRY efficiency

As previously described for wild-type SpCas9^{13,22,24}, we observed variability among the activities at different sites targeted with SpG or SpRY. Algorithms predicting CRISPR-Cas9 activity have strikingly contributed to the selection of highly efficient gRNAs that significantly increase the effectiveness of editing^{13,22,24}. CRISPRscan is a convenient tool for predicting CRISPR-SpCas9 activity *in vivo* that has been particularly useful when gRNAs are transcribed *in vitro* or chemically synthesized, and are co-delivered with Cas9 mRNA^{13,24}. This is a commonly used approach, not only in zebrafish injections, but also in other vertebrates such as *Xenopus* or mouse^{13,24}. Since SpG and SpRY are modified versions of SpCas9, we tested whether the CRISPRscan algorithm was also able to predict the activity of these minimal PAM nucleases in zebrafish. We calculated

the CRISPRscan score of the 17 and 10 targets used for SpG (NGN) and SpRY (NGG and NAN), respectively. Targets with a CRISPRscan score of 66 or more showed significant enrichment of highly efficient mutagenesis with at least 50% of the embryos demonstrating a severe (Class II/severe mosaic) or extremely severe (Class III/ albino or golden-like) phenotype (**Fig. 4a**). These results suggest that CRISPRscan can help to select the most efficient targets for SpG and SpRY *in vivo* when using *in vitro* transcribed gRNAs.

The lower number of tested targets and the different gRNA formulations in *C. elegans* (crRNA:tracrRNA vs gRNA in zebrafish) precluded us from running a similar analysis but we found a correlation between efficiency and CRISPRscan scoring in the wrmScarlet locus, in which we tested five targets. For example, while the NAN3 target with a CRISPRscan score of 39 (**Supplementary Table 1**) showed very low activity even in optimized conditions (4%), targets predicted to be highly efficient (NAN 1, NAN 2, NGH1 (**Fig. 3b,e**) and NGG (**Fig. 1h**)), with scores of more than 70 (**Supplementary Table 1**), showed at least a nine-fold increase in activity. In any case, a different approach was used in *C. elegans* where RNPs were injected, which can also influence the final SpG or SpRY activity since RNPs can protect from *in vivo* gRNA degradation and increase the half-life of unstable gRNAs ^{19,25,26}. Indeed, by using SpG or SpRY RNPs in zebrafish we were able to recapitulate the results of mRNA-gRNA injections and to increase the penetrance of the phenotypes in some targets where we previously observed low activity (**Fig. 4b, Supplementary Fig. 8**). Altogether, these results show that CRISPRscan predictions for SpG and SpRY efficiency can facilitate the use of these nucleases in zebrafish and demonstrate that RNP formulations can enhance editing activity particularly when poorly stable gRNAs are used.

SpG and SpRY are efficient for HDR-mediated gene editing in *C. elegans*

To further support the use of SpG and SpRY in animals, we studied the efficiency of SpG and SpRY for precise HDR-mediated genome editing by generating missense mutations and fluorescent reporters in *C. elegans* ²⁷. First, by choosing an NGN PAM target closer to the edit of interest compared to a site with an NGG PAM, we introduced the substitution R350C (which mimics a human

cancer mutation) in the *C. elegans* protein SWSN-4/SMARCA4 with an efficiency of 10% among *dpy-10* co-edited animals (**Fig. 4c**). Then, using SpG, we also generated translational reporters at the C-terminal end of two genes (*usp-48* and *trx-1*) lacking an NGG PAM proximal to the stop codon (**Fig. 4d**). Following the Nested CRISPR strategy ¹⁸, we first inserted a short sequence (111-bp ssDNA as repair template) that facilitated the insertion of a longer fragment, using dsDNA as a repair template, to complete the sequence for the fluorescent protein wrmScarlet. Thus, in the first step of Nested CRISPR, among *dpy-10* co-edited worms, we obtained 19.7% and 13.1% of inserts at the *usp-48* and *trx-1* C-terminal ends, respectively. We also generated a GFP:H2B transcriptional reporter by replacing the entire W05H9.1 coding sequence for the GFP:H2B tag. In this case, we used SpCas9 to cut at the C-terminal end, and SpG to cut at the N-terminal end (**Fig. 4d**). The step 1 Nested CRISPR efficiency for this reporter was 6.6% among *dpy-10* co-edited worms. Finally, we made a translational reporter for *cep-1*, using SpRY and the stop codon TAA as NAN PAM, with an efficiency of 4.8% among co-edited worms (**Fig. 4d**).

The widespread use of Cas9 variants in *C. elegans* can be facilitated by providing transgenic strains that endogenously express these nucleases in the germline. Starting from a strain expressing SpCas9 in the germline (SpCas9e) (Schwartz & Jorgensen, unpublished), we introduced mutations by CRISPR to obtain a modified strain that produces SpG instead of SpCas9 (**Fig. 4e**). By injecting just crRNA and tracrRNA, we tested the mutagenic capacity of these two strains on an NGH *dpy-10* PAM target and observed that animals expressing SpG endogenously in the germline (SpGe) were more efficient than those expressing SpCas9.

In summary, we have demonstrated that the near-PAMless Cas9 variants SpG and SpRY can efficiently mediate precise genome editing by HDR and have generated a strain expressing SpG endogenously to facilitate genome editing in targets with NGN PAMs.

DISCUSSION

Despite the tremendous impact of CRISPR-Cas9 in biotechnology and biomedicine, PAM requirements limit the technology for certain purposes. PAM proximity to the cut site is necessary when targeting short sequences such as microRNA or editing at specific sites by homologous recombination, or base or prime editing³⁰. Such proximity is also required when CRISPR-Cas is used to diagnose specific mutations³¹. Investigations into bypassing these restrictions imposed by PAMs are centered on the search for Cas9 orthologs in nature and on engineering Cas9 variants³². Among engineered Cas9 variants, the near-PAMless nucleases, SpG and especially SpRY variants, present the most relaxed PAM requirements to date. The activity of these nucleases has been well described in human cell lines⁶ and more recently in plants^{33–36}. However, SpG and SpRY have never been applied in animals. Here, we have demonstrated that both SpG and SpRY are efficient in a vertebrate and an invertebrate animal model, zebrafish and *C. elegans*, respectively. Furthermore, we have shown that these near-PAMless nucleases are capable of generating mutations in cells at two different developmental contexts such as embryonic cells and germ cells in zebrafish and *C. elegans*, respectively. In addition, we have optimized two technical approaches not previously tested with these enzymes such as the use of purified mRNA or protein.

Notably, we observed that the relaxed PAM requirements of SpG and SpRY come with a cost in terms of *in vivo* editing efficiency. When using similar standard concentrations of CRISPR reagents (Cas9 and gRNA), SpG and SpRY did not perform as successfully as SpCas9. However, we showed that SpG and SpRY activity benefits from an increased concentration of CRISPR-Cas reagents. Such need could be due to the more extensive target scanning that occurs when more PAMs fit with their requirements³⁷. We speculate that this reduced SpG and SpRY activity was not detected in human cell cultures or plant experiments because the gRNA and nuclease were expressed from strong, constitutive promoters that likely saturated their concentrations within the cells. Thus, our results in these two animal models indicate that SpG and SpRY exhibit a trade-off between versatility and efficiency that could be balanced by increasing the concentration of the gRNA, mRNA and/or protein.

A possible drawback when using SpG and SpRY is the potential increase in off-targeting ⁶. Importantly, we have observed that WT SpCas9, SpG, and SpRY are equally sensitive to mismatches at the protospacer sequence, and therefore such off-targeting could be predicted by current algorithms ²². Moreover, our optimized transient approaches, such as RNP or mRNA-gRNA delivery, will help reduce potential off-targets compared to when gRNA and Cas9 are expressed from plasmids or stable integrations in the genome that provide a longer window of opportunity for off-target mutagenesis. Finally, high-fidelity versions can decrease off-target activity as shown in mammalian cells ⁶.

Since SpG and SpRY are engineered SpCas9 variants, we speculate that most of the optimizations uncovered and used for SpCas9 will be likely applicable to SpG and SpRY. Indeed, we have shown that CRISPRscan, an algorithm for predicting CRISPR-SpCas9 activity *in vivo*, can significantly facilitate the selection of highly efficient targets for SpG and SpRY. CRISPRscan scores above 70 normally identifies highly efficient targets for WT SpCas9 ¹³ similarly to our observations for SpG/SpRY where targets with scores of 67 or above showed high activity in a significant manner. Although, more studies will be needed to further consolidate our data, we have updated our web tool (www.crisprscan.org) with the targets and predicted on- and off-targets scores for SpG (NGN) and SpRY (NRN) that will help in selecting the most active gRNAs. Moreover, chemically modified and more stable gRNAs ³⁸ can contribute to a improvement in editing *in vivo*, especially when co-injected with mRNA where gRNAs spend more time unprotected from degradation. Finally, Cas9 RNPs with synthetic crRNA:tracrRNAs used here for *C. elegans* could also increase the mutagenesis level in zebrafish ³⁹.

Furthermore, recent publications have demonstrated not only the capacity of SpG and SpRY to produce indels in mammalian cells and plants and but also their adaptation to base editor systems that take advantage of their relaxed PAMs ^{6,34,35}. Our optimized CRISPR-SpG and SpRY systems *in vivo* now set the basis for carrying out base editing and other CRISPR applications in animals ⁴⁰⁻⁴² with a greatly improved targeting landscape. Indeed, we went one step further in using SpG and SpRY in *C. elegans* by performing editing through HDR that allows the mimicking of missense mutations and the creation of endogenous reporters in targets that are inaccessible for SpCas9. Finally, and as proof of principle, we

have also produced an SpG transgenic nematode that will facilitate the use of the technology in this animal. This strategy, combined with the use of tissue-specific promoters and inducible gene expression systems, opens the possibility of taking advantage of these nucleases in the cell types of interest and at distinct developmental stages. Altogether, we believe that our SpG and SpRY optimizations will contribute to the expansion of the CRISPR-Cas toolbox for *in vivo* applications.

Acknowledgements

We thank Luis Hernandez-Huertas for his help with statistical analysis. We thank all members of the Moreno-Mateos and the Cerón laboratories for intellectual and technical support. Ceron laboratory thanks the CERCA Program (Generalitat de Catalunya) for their institutional support, and Nicholas Stroustrup and Alberto Villanueva for sharing reagents and equipment and Marta Artal and Antonio Miranda for allowing to share the information on the efficiency of the *trx-1* and *usp-48* endogenous reports generation. We thank Erik Jorgensen for sharing the EG9615 strain. This work was supported by Ramon y Cajal (RyC-2017-23041) and MDM-2016-0687 programs (Spanish Ministerio de Ciencia, Innovación y Universidades), Universidad Pablo de Olavide (UPO) Research and the Springboard programs from UPO and CABD, respectively (M.A.M-M). The Moreno-Mateos lab is supported by PGC2018-097260-B-I00 grant from Spanish Ministerio de Ciencia, Innovación y Universidades. The CABD is an institution funded by Pablo de Olavide University, Consejo Superior de Investigaciones Científicas (CSIC), and Junta de Andalucía. C. S.-B. was a recipient of the Ayudas Puente Predoctorales (Universidad Pablo de Olavide, V Plan Propio de Investigación y transferencia). J.V. had an INPhINIT PhD fellowship from “la Caixa” Foundation (LCF/BQ/IN17/11620065) co-funded by Marie Skłodowska-Curie grant agreement no. 713673. DB is a predoctoral fellow of the CONACYT “Becas al Extranjero” Program of Mexico. D.K. has an FI AGAUR fellowship (2018FI_B1_00511) from Generalitat de Catalunya. A.J.G. and B.P.K. acknowledges support from National Institutes of Health (NIH) R00 CA218870 and NIH P01 HL142494 (B.P.K) and 5R35GM122580-05 (A.J.G). Some figures in this manuscript were created with BioRender.com.

Author contributions

M.A.M-M. and J.C. conceived the project and designed the research. C. S-B. generated SpG and SpRY plasmids for *in vitro* transcription and performed all zebrafish experiments with the contribution of I.M-S. and M.A.M-M. Most *C. elegans* experiments were performed by J.V., with the contribution of J.C., D.B., D.K., M.R-L., and M.C-P. N.R.M and C.C. purified SpG and SpRY recombinant proteins. C.E.V. and A.J.G. updated CRISPRscan. A.R. and A.J.P-P. generated alignments of indel mutations and calculated the number of targets for different Cas enzymes in zebrafish and *C. elegans*. M.A.M-M., J.C., J.V, C.S-B., and B.P.K. performed data analysis, and M.A.M-M. and J.C. wrote the manuscript with input from J.V., C.S-B., and B.P.K. All authors reviewed and approved the manuscript.

Competing interests

B.P.K is an inventor on patents and patent applications filed by Mass General Brigham that describe genome engineering technologies. B.P.K. is a consultant for Avectas Inc., EcoR1 capital, and ElevateBio, and is an advisor to Acrigen Biosciences and Life Edit Therapeutics. The rest of the authors declare no competing non-financial interests.

METHODS

Number of target sites calculation for different Cas nucleases in zebrafish and *C. elegans* genomes

Genome sequences from *C. elegans* (v. WBcel235) and *D. rerio* (v. GRCz11) were downloaded from Ensembl database ⁴³.

PAM sites (**Supplementary Table 1**) were searched by an in-house script written in PERL language. It is based on the fuzznuc function of EMBOSS package to show the coordinates of the sites in both strands ⁴⁴. Genomic positions were converted into GTF format for later comparison to the different types of regions of the genome using bedtools ⁴⁵. The count of sites by genomic position was depicted by the ggplot2 3.3.0 library from R programming language.

Target and gRNA design in zebrafish

Target (protospacers) and gRNAs for SpG and SpRY were designed using an updated version of the algorithm CRISPRscan (www.crisprscan.org) tool ¹³. Regular expressions for SpG (NGN) and SpRY (N[AG]N) were added for on-target and off-target searches. On-target scores were evaluated using the same CRISPRscan scoring algorithm used for SpCas9. Off-targets with mismatches restricted, or not, to the target “seed” are reported similarly, to SpCas9 ^{46,47}. The CFD score ²² used to characterize potential off-targeting was kept identical to score protospacers but adapted to score PAMs of potential off-targets. SpG and SpRY matching PAMs were set a 1.0 score instead of using the original (lower than 1.0) Doench et al. score characterized for SpCas9. Protospacers in the different loci were selected without predicted off-targets ⁴⁶, and within functional domains of the protein and in exons in the first half of the ORF with the exception of gRNA albino 7 which approximately maps in the last third part of the ORF. To evaluate activity of the Cas9 variants in the NGG PAMs, we used two gRNAs (albino a and albino b) as previously described ¹³. All the information about the targets is detailed in **Supplementary Table 1**.

In vitro transcription and gRNA generation

gRNAs were generated as previously described ⁴⁸. gRNA DNA templates were amplified by fill-in PCR. Briefly, a 52-nt oligo (sgRNA primer), containing the T7

promoter, the 20 nt of the specific gRNA DNA binding sequence (spacer) starting with two Gs and a constant 15-nt tail for annealing, was used in combination with an 80-nt reverse oligo to add the gRNA invariable 3' end (universal primer). Here, all spacers used in zebrafish experiments started by 5' GG (**Supplementary Fig. 1a**) allowing 100% match between target and *in vitro* transcribed gRNAs. A 117 bp PCR product was generated following these parameters: 30 seconds at 98°C, 30 cycles of 10 seconds at 98°C, 30 seconds at 51°C, and 30 seconds at 72°C, and a final step at 72°C for one minute. PCR products were purified using FavorPrep™ GEL/PCR Purification kit (Favorgen) columns and approximately 120–150 ng of DNA was used as template for a T7 *in vitro* transcription (IVT) reaction (AmpliScribe-T7-Flash transcription kit from Epicentre). *In vitro* transcribed gRNAs were DNase-treated using TURBO-DNase for 20 min at 37°C and precipitated with sodium acetate/ethanol and resuspended in RNase and DNase free water. gRNAs were visualized in 2% agarose stained with ethidium bromide to check for RNA integrity, quantified using the Qubit RNA BR Assay Kit (ThermoFisher, Q10210), and stored in aliquots at -80°C.

Target and gRNA design in *C. elegans*

For experiments in the *dpy-10* locus, the *dpy-10* gRNA with NGG PAM used in co-CRISPR was used as the reference sequence ¹⁷. Mismatches were then introduced into the protospacer at one (+1) or five (+5) nucleotides upstream of the PAM (**Fig. 1f**). Meanwhile, a protospacer with an NGH PAM was chosen based on proximity to the reference NGG sequence to maintain the cut site within the RXXR domain of *dpy-10* which is responsible for the production of the dominant dumpy and roller phenotypes, such as that of the *cn64* allele ⁴⁹. Five targets with distinct PAM requirements were selected for wrmScarlet: one NGG, one NGH, and three NAN (**Fig. 3a**). For HDR experiments in *swns-4*, *usp-48*, *trx-1*, W05H9.1, and *cep-1*, gRNAs were selected based on the proximity of the DSB from the desired edit site (**Fig. 4d**). crRNAs and ssODNs were purchased in tubes from IDT as 2 nmol ALT-R crRNAs and 4 nmol ultramers, respectively, and resuspended in 20 µl or 40 µl of nuclease-free duplex buffer (30 mM HEPES, pH 7.5; 100 mM potassium acetate. IDT, Cat. No. 11-01-03-01), respectively, to yield a stock concentration of 100 µM. A list of all crRNAs used can be found in **Supplementary Table 1**.

SpG and SpRY zebrafish codon optimized constructs and mRNA generation.

pT3TS_zCas9 (Addgene, 46757)⁵⁰ was modified to generate two plasmids encoding the SpG and SpRY zebrafish codon-optimized variants: pT3TS_zSpG and pT3TS_zSpRY include D1135L/S1136W/G1218K/E1219Q/R1335Q/T1337R and A61R/L1111R/D1135L/S1136W/G1218K/E1219Q/N1317R/A1322R/R1333P/R1335Q/T1337R modifications, respectively. All mutations were generated using site-directed mutagenesis (QuikChange Multi Site-Directed Mutagenesis Kit, Agilent Technologies) and primers used are detailed in **Supplementary Table 1**. The final pT3TS_zSpG and pT3TS_zSpRY constructs were confirmed by sequencing.

SpG and SpRY mRNA were *in vitro* transcribed from DNA linearized by XbaI (1 µg) using the mMESSAGE mMACHINE™ T3 kit (Invitrogen, Thermo Fisher). *In vitro* transcribed mRNAs were DNase treated using 1 µl TURBO-DNase for 20 minutes at 37 °C and purified using RNeasy Mini Kit (Qiagen). mRNA product was quantified using NanoDrop (Thermo Fisher) and stored in aliquots at -80°C.

SpG and SpRY purification

The two Cas9 variants: SpG (D1135L/S1136W/G1218K/E1219Q/R1335Q/T1337R) and SpRY (A61R/L1111R/D1135L/S1136W/G1218K/E1219Q/N1317R/A1322R/R1333P/R1335Q/T1337R) were cloned into the pET-28b-Cas9-His, with DNA gBlocks (IDT) encoding for the mutated regions.

The different Cas9 proteins were expressed in *E. coli* (DE3) using the auto-induction method, by growing for 4h at 37 °C, followed by 20h expression at 25 °C. Cells were harvested by centrifugation at 4000 × g for 10 min. Cell pellets were suspended in equilibration buffer (20 mM Tris pH 8.0, 500 mM NaCl) plus protease inhibitors (Roche) and lysed using a high pressure Emulsiflex. The cell debris were removed by centrifugation at 30000 × g for 30 min. The supernatant was purified using a HisTrap column (Cytiva) pre-equilibrated with buffer A (20 mM Tris pH 8.0, 500 mM NaCl). After sample loading, the columns were washed with buffer A plus 50mM imidazole and eluted with buffer A plus 500 mM imidazole. The eluted protein was concentrated with Amicon Ultra 50 Kda filters (Millipore) and loaded into a Superdex 200 10/300 size-exclusion column (Cytiva)

equilibrated with SEC buffer, 20 mM HEPES pH 7.4, 500 mM KCl, and 1 mM DTT. The eluted sample was dialyzed against storage buffer 20 mM Tris pH 7.4, 200 mM KCl, 10mM MgCl₂, and 10% glycerol, concentrated to 2 mg/mL, snap frozen in liquid nitrogen, and stored at -80°C.

RNP *in vitro* test

The gRNA was prepared by pre-annealing 3.2 µL of 32 µM ALT-R tracrRNA (IDT, Cat. No. 1072532) and 1 µL of 100 µM crRNA with 5.8 µL of nuclease-free duplex buffer (IDT) at 95°C for 5 minutes. Dilutions of the components, namely gRNA, nuclease, and PCR product were prepared at 300 nM, 900 nM, and 90 nM, respectively. Then, the RNP complex was assembled by incubating 9 µL of guide RNA with 3 µL of nuclease in 12 µL of nuclease-free H₂O with 3 µL of 10x Cas9 reaction buffer (New England Biolabs, #B0386) at 37 °C for 15 minutes. Alt-R® S.p. Cas9 Nuclease V3 (IDT, Cat. No. 1081058) was used as commercial Cas9. 3 µL of the DNA substrate (PCR product) containing the target site was then added to achieve a final molar ratio of nuclease, guide RNA, and target site of 10:10:1 (90 nM:90 nM:9 nM). The 30-µL reactions were incubated at different temperatures (15, 25, 37, and 50 °C) for 60 minutes. To release the DNA substrate from the RNP complex, 1 µL Proteinase K (20 mg/mL) was added to the reaction and incubated at 56°C for 10 minutes. The cleaved products were analyzed through agarose gel electrophoresis using a 2% gel stained with SYBR® safe DNA gel stain (ThermoFisher Scientific, Cat. No. S33102).

Zebrafish maintenance

Wild-type zebrafish embryos were obtained through natural mating of AB/Tübingen AB/Tu zebrafish of mixed ages (5–18 months). Selection of mating pairs was random from a pool of 20 males and 20 females. All experiments involving zebrafish conform to national and European Community standards for the use of animals in experimentation and were approved by the ethical committees from the University Pablo de Olavide, CSIC, and the Andalusian Government. Zebrafish wild-type strains AB/Tübingen (AB/Tu) were maintained and bred under standard conditions ⁵¹. All experiments were carried out at 28 °C, a temperature allowing optimal zebrafish development.

C. elegans maintenance

We used the Bristol N2 strain as the wild-type background while the strain CER541 *gtbp-1*(*cer149[gtbp-1::wrnScarlet]*) IV was used for wrnScarlet knockout experiments. Worms were maintained at 15 °C, 20 °C or 25 °C on Nematode Growth Medium (NGM) plates seeded with *Escherichia coli* OP50 bacteria⁵². All strains generated in this study are listed in **Supplementary Table 1**.

mRNA and RNP injections and image acquisition in zebrafish

mRNA injection mixes were prepared at two different concentrations by combining the mRNA of the variants, mSpG and mSpRY, and the gRNAs. One nL containing 150 pg of SpG or SpRY mRNA and 20 pg of gRNA were injected into one-cell stage embryos, similar to what has been previously described for SpCas9¹³. To optimize SpG and SpRY activity, either 0.5 nL or 1 nL of a mixture containing 300 pg of mRNA and 240 pg of gRNA was injected. RNP injection mixes were prepared in 20 mM HEPES pH 7.4, 250 mM KCl, and 1 mM DTT by mixing the protein and gRNA at a ratio of 1:1.3. RNPs (6 μM) were incubated at 37 °C for 10 min and then kept on ice before use. One nL (6 fmol), or 0.5 nL (3 fmol) from the 6 μM solution was injected in one-cell stage embryos. In both cases, the mixtures were kept on ice, and any excess stored at -80°C for up to three freeze-thaw cycles maintained similar efficiency. Zebrafish embryo phenotypes were analyzed at 24 hours or at 48 hours, depending on the target gene, using an Olympus SZX16 stereoscope and photographed with a Nikon DS-F13 digital camera and further edited in Adobe Photoshop.

Microinjection in C. elegans

Injection mixes were prepared by combining Cas9 nuclease, tracrRNA, and crRNA, and incubated at 37 °C for 15 minutes. When necessary, ssODN repair templates were added after incubation and the mixture centrifuged at 13,200 rpm for 2 minutes to settle particulate matter. The injection mixes were kept on ice prior to loading of the needles and any excess stored at -20°C afterwards. Eppendorf Femtotips® capillary tips (Eppendorf, Cat. No. 930000035) for microinjection were loaded with 2 μl of the injection mix and fixed onto the XenoWorks Microinjection System (Sutter Instrument) coupled to a Nikon Eclipse

Ti-S inverted microscope with *Nomarski* optics. Approximately 15–20 young adult hermaphrodites were injected for each experimental condition. The worms were fixed on 2% agarose pads with halocarbon oil in groups of five and were injected in one or both gonad arms. Injected worms were recovered in M9 buffer and were individually separated onto nematode growth medium (NGM) agar plates. The plates were incubated at 25 °C for three days.

RNP testing in *C. elegans*

Bristol N2 worms were injected with *dpy-10* RNPs and screened for the presence of dumpy and/or roller phenotypes. The editing efficiency from each injected P_0 was calculated by counting the proportion of dumpy or roller F_1 progeny over the total number of F_1 progeny laid by each P_0 worm. Occasionally, injections targeting the *dpy-10* locus included pCFJ90 (*myo-2p::mCherry*) and pCFJ104 (*myo-3p::mCherry*) as co-markers to facilitate the screening of recessive Dpy phenotypes in the F_2 . On the other hand, CER541 worms harboring a homozygous *gtbp-1::wrmscarlet* fluorescent reporter were injected with anti-wrmscarlet RNPs combined with *dpy-10* RNP as co-CRISPR marker. From each injected P_0 , between five to ten dumpy or roller F_1 s were separated and allowed to lay F_2 progeny. The F_2 progeny were then screened for wrmscarlet knockouts using a Nikon SMZ800 stereomicroscope linked to a Nikon Intensilight C-HGFI epi-fluorescence illuminator with an mCherry filter. The editing efficiency from each injected P_0 was calculated by counting the proportion of separated F_1 progeny that gave rise to non-fluorescent F_2 worms. Non-fluorescent worms were indicative of indels arising from error-prone repair of DSBs.

Endogenous reporters for the *usp-48*, *trx-1*, and W05H9.1 loci were generated to test the efficiency of HDR by using SpG with NGN PAMs, and in the *cep-1* locus by using SpRY with an NAN PAM. Using the Nested CRISPR approach¹⁸, a C-terminal wrmscarlet fusion was made in *usp-48*, *trx-1*, and *cep-1*, while a transcriptional reporter was made for W05H9.1 by removing the entire coding sequence and replacing it with the GFP::H2B sequence. For each locus, an injection mix containing the SpG nuclease, target gene crRNA(s), *dpy-10* crRNA, tracrRNA, and an ssODN repair template consisting of a partial wrmscarlet or GFP::H2B fragment flanked by two 35-bp homology arms were assembled and injected into Bristol N2 worms. *dpy-10* co-edited F_1 progeny were then separated

individually or in pools onto NGM agar plates, allowed to lay F₂ progeny, and genotyped via PCR. The overall editing efficiency was calculated by counting the proportion of F₁ worms harboring the insertion of the correct size over the total number of genotyped F₁ animals. Two independent homozygous lines for the step 1 insertion are then verified via Sanger sequencing and the complete wrmScarlet or GFP::H2B fragment is inserted via the nested CRISPR step 2 protocol using SpCas9¹⁸. Finally, the R350C substitution in the *swns-4*/SMARCA4 gene was accomplished via the introduction of a missense mutation using an ssODN repair template. A list of primers used for genotyping and sequencing can be found in **Supplementary Table 1**.

Generation of endogenous germline SpG -expressing *C. elegans* strains

EG9615 (*oxSi1091[mex-5p::Cas9(smu-2 introns) unc-119(+)] II; unc-119(ed3) III*), a strain carrying a transgene that expresses SpCas9 in the germline was a gift from Dr. Matthew Schwartz and Dr. Erik Jorgensen (unpublished). EG9615 hermaphrodites were injected with three crRNAs and three ssODN repair templates to introduce the six amino acid substitutions to convert SpCas9 to SpG. Each crRNA and ssODN repair template introduced the D1135L and S1136W, G1218K and E1219Q, and R1335Q and T1337R substitutions by pairs (**Supplementary Table 1**). The first round of injections contained all three crRNAs at a final concentration of 1 μ M each, tracrRNA at 3.2 μ M, the three ssODN repair templates at 2.2 μ M each, pCFJ90 at 2.5 ng/ μ L, and pCFJ104 at 5.0 ng/ μ L. F₁ progeny with visible mCherry expression in the pharynx or body wall were singled out and were genotyped via single worm lysis and PCR after laying F₂ progeny. From the first set of injections, a strain with the D1135L and S1136W substitutions was successfully isolated. Then, a second round of injections was made over this strain to introduce the remaining substitutions. However, the remaining two crRNAs were combined with tracrRNA and IDT Cas9 v3 nuclease at a final concentration of 2.1 μ M to form RNPs in an attempt to increase the editing efficiency. Worms were injected with this injection mixture and genotyped as previously described. The four remaining substitutions were successfully isolated and three independent lines were kept and frozen (CER658, CER659, and CER660).

Indel mutation sequencing

In zebrafish, five embryos per injection were collected at 24 hpf and genomic DNA was extracted following a protocol adapted from Meeker et al., 2007. Using this genomic DNA as template, a ~100 bp PCR product was obtained using the following parameters: 30 seconds at 98°C, 35 cycles of [10 seconds at 98°C, 30 seconds at 60°C, and 30 seconds at 72°C], and a final step at 72°C for two minutes. In *C. elegans*, individual worms were collected (F_2 dumpyes or F_2 wrmScarlet knockouts from F_1 heterozygotes) and genomic DNA was extracted via single worm lysis. Using this genomic DNA as template, a PCR product was amplified using a touchdown PCR program: 2 minutes at 98°C, 11 cycles of [15 seconds at 98°C, 15 seconds at 64°C (decrease by 0.5°C per cycle), and 30 seconds at 72°C], 24 cycles of [15 seconds at 98°C, 15 seconds at 59°C, and 30 seconds at 72°C], and a final step at 72°C for ten minutes.

PCR products were visualized on agarose gel, purified (QIAquick PCR purification, Qiagen) and sequenced. After sanger sequencing (Stabvida), indel mutations were identified and analyzed using the ICE tool (Synthego Co). Target sequences were aligned by mafft v7.271 using default options ⁵⁴.

Statistics

No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Bar graphs show the average and are represented with S.E.M bars and violin plots are represented with individual data points and the median. Zebrafish phenotype or viability data in different injections conditions come from, at least, two independent experiments per figure panel. *C. elegans* data come from one or two independent experiments per figure panel with all data derived from parallel injections unless otherwise specified in the figure legend. Exact Fisher test, Student's *t*-test or one-way ANOVA (all values shown are two-sided) with Tukey's test for multiple comparisons were performed using SSPS (IBM, Armonk, NY, USA), Prism (GraphPad Software v9, La Jolla, CA, USA) or R programming language.

Data availability

All relevant data are available from corresponding authors upon reasonable request.

REFERENCES:

1. Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. *Cell* **168**, 20–36 (2017).
2. Paquet, D. *et al.* Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. *Nature* **533**, 125–129 (2016).
3. Huang, T. P., Newby, G. A. & Liu, D. R. Precision genome editing using cytosine and adenine base editors in mammalian cells. *Nat. Protoc.* **16**, 1089–1128 (2021).
4. Kleinstiver, B. P. *et al.* Engineered CRISPR-Cas9 nucleases with altered PAM specificities. *Nature* **523**, 481–485 (2015).
5. Hu, J. H. *et al.* Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. *Nature* **556**, 57–63 (2018).
6. Walton, R. T., Christie, K. A., Whittaker, M. N. & Kleinstiver, B. P. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. *Science (80-.)* **368**, 290–296 (2020).
7. Gasiunas, G. *et al.* A catalogue of biochemically diverse CRISPR-Cas9 orthologs. *Nat. Commun.* **11**, (2020).
8. Chatterjee, P. *et al.* An engineered ScCas9 with broad PAM range and high specificity and activity. *Nat. Biotechnol.* **38**, 1154–1158 (2020).
9. Kleinstiver, B. P. *et al.* Broadening the targeting range of *Staphylococcus aureus* CRISPR-Cas9 by modifying PAM recognition. *Nat. Biotechnol.* **33**, 1293–1298 (2015).
10. Kleinstiver, B. P. *et al.* Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. *Nat. Biotechnol.* **37**, 276–282 (2019).
11. Miller, S. M. *et al.* Continuous evolution of SpCas9 variants compatible with non-G PAMs. *Nat. Biotechnol.* **38**, 471–481 (2020).
12. Nance, J. & Frøkjær-Jensen, C. The *Caenorhabditis elegans* transgenic toolbox. *Genetics* **212**, 959–990 (2019).
13. Moreno-Mateos, M. A. *et al.* CRISPRscan: Designing highly efficient sgRNAs for CRISPR-Cas9 targeting *in vivo*. *Nat. Methods* **12**, 982–988 (2015).
14. Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J. S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome Res.* **24**, 1012–1019 (2014).
15. Liang, X. *et al.* Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. *J. Biotechnol.* **208**, 44–53 (2015).
16. Kim, H. *et al.* A co-CRISPR strategy for efficient genome editing in *Caenorhabditis elegans*. *Genetics* **197**, 1069–1080 (2014).
17. Arribere, J. A. *et al.* Efficient marker-free recovery of custom genetic modifications with CRISPR/Cas9 in *caenorhabditis elegans*. *Genetics* **198**, 837–846 (2014).
18. Vicencio, J., Martínez-fernández, C., Serrat, X. & Cerón, J. Efficient Generation of Endogenous Fluorescent Reporters by Nested CRISPR in *Caenorhabditis elegans*. *Genetics* **211**, 1143–1154 (2019).
19. Moreno-Mateos, M. A. *et al.* CRISPR-Cpf1 mediates efficient homology-directed repair and temperature-controlled genome editing. *Nat. Commun.* **8**, 2024 (2017).
20. Nishimasu, H. *et al.* Engineered CRISPR-Cas9 nuclease with expanded targeting space. *Science (80-.)* **9**, 1259–1262 (2018).
21. Vicencio, J. & Cerón, J. A Living Organism in your CRISPR Toolbox: *Caenorhabditis elegans* Is a Rapid and Efficient Model for Developing CRISPR-Cas Technologies. *Cris. J.* **4**, 32–42 (2021).
22. Doench, J. G. *et al.* Optimized sgRNA design to maximize activity and minimize

off-target effects of CRISPR-Cas9. *Nat. Biotechnol.* **34**, 184–191 (2016).

- 23. Farboud, B., Severson, A. F. & Meyer, B. J. Strategies for efficient genome editing using CRISPR-Cas9. *Genetics* **211**, 431–457 (2019).
- 24. Haeussler, M. *et al.* Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. *Genome Biol.* **17**, 1–12 (2016).
- 25. Burger, A. *et al.* Maximizing mutagenesis with solubilized CRISPR-Cas9 ribonucleoprotein complexes. *Dev.* **143**, 2025–2037 (2016).
- 26. Liu, P. *et al.* Enhanced Cas12a editing in mammalian cells and zebrafish. *Nucleic Acids Res.* **47**, 4169–4180 (2019).
- 27. Dickinson, D. J., Ward, J. D., Reiner, D. J. & Goldstein, B. Engineering the *Caenorhabditis elegans* genome using Cas9-triggered homologous recombination. *Nat. Methods* **10**, 1028–1034 (2013).
- 28. Yang, B., Schwartz, M. & McJunkin, K. In vivo CRISPR screening for phenotypic targets of the mir-35-42 family in *C. elegans*. *Genes Dev.* **34**, 1227–1238 (2020).
- 29. Ashley, G. E. *et al.* An expanded auxin-inducible degron toolkit for *Caenorhabditis elegans*. *Genetics* **217**, (2021).
- 30. Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. *Nat. Biotechnol.* **38**, 824–844 (2020).
- 31. Li, Y., Li, S., Wang, J. & Liu, G. CRISPR/Cas Systems towards Next-Generation Biosensing. *Trends Biotechnol.* **37**, 730–743 (2019).
- 32. Collias, D. & Beisel, C. L. CRISPR technologies and the search for the PAM-free nuclease. *Nat. Commun.* **12**, 1–12 (2021).
- 33. Li, J. *et al.* Genome editing mediated by SpCas9 variants with broad non-canonical PAM compatibility in plants. *Mol. Plant* **14**, 352–360 (2021).
- 34. Ren, Q. *et al.* PAM-less plant genome editing using a CRISPR–SpRY toolbox. *Nat. Plants* **7**, 25–33 (2021).
- 35. Xu, Z. *et al.* SpRY greatly expands the genome editing scope in rice with highly flexible PAM recognition. *Genome Biol.* **22**, 1–15 (2021).
- 36. Zhang, C. *et al.* Expanding base editing scope to near-PAMless with engineered CRISPR/Cas9 variants in plants. *Mol. Plant* **14**, 191–194 (2021).
- 37. Moreb, E. A., Hutmacher, M. & Lynch, M. D. CRISPR-Cas ‘non-Target’ Sites Inhibit On-Target Cutting Rates. *Cris. J.* **3**, 550–561 (2020).
- 38. Hendel, A. *et al.* Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. *Nat. Biotechnol.* **33**, 985–989 (2015).
- 39. Hoshijima, K. *et al.* Highly Efficient CRISPR-Cas9-Based Methods for Generating Deletion Mutations and F0 Embryos that Lack Gene Function in Zebrafish. *Dev. Cell* **51**, 645–657.e4 (2019).
- 40. Kim, K. *et al.* Highly efficient RNA-guided base editing in mouse embryos. *Nat. Biotechnol.* **35**, 435–437 (2017).
- 41. Rosello, M. *et al.* Precise base editing for the in vivo study of developmental signaling and human pathologies in zebrafish. *Elife* **10**, 1–27 (2021).
- 42. Zhang, Y. *et al.* Programmable base editing of zebrafish genome using a modified CRISPR-Cas9 system. *Nat. Commun.* **8**, 6–10 (2017).
- 43. Howe, K. L. *et al.* Ensembl 2021. *Nucleic Acids Res.* **49**, D884–D891 (2021).
- 44. Rice, P., Longden, L. & Bleasby, A. EMBOSS: The European Molecular Biology Open Software Suite. *Trends Genet.* **16**, 276–277 (2000).
- 45. Quinlan, A. R. & Hall, I. M. BEDTools: A flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).
- 46. Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science (80-.)* **339**, 819–23 (2013).
- 47. Hsu, P. D. *et al.* DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat. Biotechnol.* **31**, 827–832 (2013).
- 48. Vejnar, C. E., Moreno-Mateos, M. A., Cifuentes, D., Bazzini, A. A. & Giraldez, A.

J. Optimized CRISPR-Cas9 system for genome editing in zebrafish. *Cold Spring Harb. Protoc.* **2016**, 856–870 (2016).

49. Kramer, J. M. & Johnson, J. J. Analysis of mutations in the *sqt-1* and *rol-6* collagen genes of *Caenorhabditis elegans*. *Genetics* **135**, 1035–1045 (1993).

50. Jao, L. E., Wente, S. R. & Chen, W. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 13904–13909 (2013).

51. Westerfield, M. *The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio)*. (University of Oregon Press, 1995).

52. Stiernagle, T. Maintenance of *C. elegans*. *WormBook* 1–11 (2006) doi:10.1895/wormbook.1.101.1.

53. Meeker, N. D., Hutchinson, S. A., Ho, L. & Trede, N. S. Method for isolation of PCR-ready genomic DNA from zebrafish tissues. *Biotechniques* **43**, 610–614 (2007).

54. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780 (2013).

55. Mello, C. C., Kramer, J. M., Stinchcomb, D. & Ambros, V. Efficient gene transfer in *C. elegans*: Extrachromosomal maintenance and integration of transforming sequences. *EMBO J.* **10**, 3959–3970 (1991).

FIGURE LEGENDS

Figure 1. SpG and SpRY are efficient nucleases in zebrafish and *C. elegans*

- a. Diagram illustrating two guide RNAs (gRNAs, black) targeting *slc45a2* exon 1 in zebrafish (top). Schematic illustrating the experimental set-up to analyze CRISPR-Cas9, SpG, and SpRY-mediated mutations in zebrafish. gRNAs (a or b) were mixed with mRNA coding for Cas9 WT, SpG, or SpRY and injected in one-cell-stage embryos (bottom).
- b. Phenotypes obtained after the injection of the mRNA–gRNA duplex targeting *slc45a2* showing different levels of mosaicism (albino-like (alb-like), severe, mild) compared to the WT. Lateral views (scale bar, 1 mm) and insets of the eyes (scale bar, 0.2 mm) of 48 hours post-fertilization (hpf) embryos are shown.
- c. Phenotypic evaluation of gRNAs (20 pg/embryo) and mRNA (150 pg/embryo) injections. Stacked barplots show the percentage of albino-like (white), severe (light grey), mild (dark grey) and phenotypically wild-type (WT; black) embryos 48 hpf. The total number of injected embryos (n) is shown below. The results were obtained from at least two independent experiments.
- d. Phenotypic evaluation under optimized concentration of gRNAs and mRNAs. mRNA and gRNA pg/embryo are indicated. Stacked barplots show the percentage of the phenotypes described in panel c. The total number of injected embryos (n) is shown below. The results were obtained from at least two independent experiments.
- e. gRNAs were complexed with purified SpCas9, SpG, or SpRY proteins to form RNPs for *in vitro* and *in vivo* testing in *C. elegans* via standard microinjection technique⁵⁵.
- f. Sequences of three guides targeting *dpy-10*: a spacer with perfect complementarity (*dpy-10* matched guide), a spacer with a mismatch 1 nt upstream of the PAM (*dpy-10* +1 guide), and a spacer with a mismatch 5 nt upstream of the PAM (*dpy-10* +5 guide). Nine different RNP combinations comprised of each guide and WT SpCas9, SpG, or SpRY were tested *in vitro* at 25 °C and 37 °C by incubating the RNPs with a *dpy-10* PCR product for one hour. The top row of bands shows uncleaved PCR product at 698 bp, the middle row of bands shows cleaved products at 432 bp, and the bottom row of bands shows cleaved products at 266 bp.
- g. The *dpy-10* matched and +5 guides were tested for *in vivo* activity in *C. elegans* by injecting a single gonad arm. The editing efficiency is defined as the number of F₁ progeny with Rol or Dpy phenotypes divided by the total number of F₁ progeny laid by each P₀. Each dot represents the editing efficiency in each individual P₀ that produced at least 100 F₁s. The results are obtained from two independent experiments, with both conditions carried out in parallel injections. p<0.0001 **** (Student's t-test)
- h. Schematic representation of *in vivo* experiments in *C. elegans* using a *gtbp-1::wrnScarlet* reporter by screening for loss of fluorescence. CER541 worms are injected with a mixture containing an anti-wrnScarlet guide and a *dpy-10* guide for co-CRISPR. F₁ worms with the Rol or Dpy phenotypes are separated onto individual plates and allowed to lay F₂ progeny, which displays mendelian segregation from a doubly heterozygous F₁ hermaphrodite.
- i. An anti-wrnScarlet guide with NGG PAM was complexed with SpCas9, SpG, or SpRY to compare their *in vivo* efficiencies in *C. elegans*. Each of the three

RNP combinations were injected at a final concentration of 1.3 μ M (1x); and in a separate experiment, the SpG-anti-wrmScarlet (NGG) RNP was injected at a final concentration of 8.0 μ M (6x). The editing efficiency is defined as the number of F_1 worms exhibiting loss of fluorescence in the F_2 divided by the total number of separated *dpy-10* co-edited F_1 s. Each dot represents the editing efficiency in each individual P_0 that produced at least five Dpy or Rol F_1 s. ns: no significant difference, $p < 0.0001$ **** (One-way ANOVA followed by Tukey's test for multiple comparisons).

Figure 2. SpG and SpRY are efficient nucleases at minimal PAM targets in zebrafish

- a. Diagram illustrating 15 gRNAs (blue) with NGH PAM in three in zebrafish genes. Five gRNAs targeting exon 1 and 5, exons 3, 4 and 5 and exons 2 and 3 of *slc45a2*, *slc24a5* and *tbxta*, respectively. Different NGH PAMs for each target are detailed in **Supplementary Table 1**.
- b. mRNA SpG shows high activity in NGH sites. Individual gRNAs described in panel a were injected together with the SpG mRNA (240 pg gRNA and 300 pg mRNA per embryo). Stacked barplots show the percentage of albino-like/golden-like (gol-like)/class III (white), severe/class II (light grey), mild/class I (dark grey), and phenotypically wild-type (WT; black) embryos 48 hpf after injection. The total number of injected embryos (n) is shown below. The results were obtained from at least two independent experiments.
- c. Phenotypes obtained after the injection of the mRNA–gRNA duplex targeting *slc24a5* showing different levels of mosaicism (golden-like, severe, mild) compared to the WT. Lateral views (scale bar, 1 mm) and insets of the eyes (scale bar, 0.2 mm) of 48 hpf embryos are shown.
- d. Phenotypes obtained after injection of the mRNA–gRNA duplex targeting *tbxta* in zebrafish embryos (Lateral views). Levels of mosaicism compared to wild type (WT) were evaluated at 28 hpf. Class I: Short tail (least extreme). Class II: Absence of notochord and short tail (medium level). Class III: Absence of notochord and extremely short tail (most extreme). Scale bar, 0.5 mm.
- e. Diagram illustrating 8 gRNAs (green) with NAN PAM in three zebrafish genes. Three gRNAs targeting *slc45a2* exons 1 and 5, two gRNAs targeting *slc24a5* exons 1 and 3 and three gRNAs targeting *tbxta* exons 1 and 2. Different NAN PAMs for each target are detailed in **Supplementary Table 1**.
- f. mRNA SpRY shows high activity in NAN sites. Individual gRNAs described in panel e were injected together with the SpRY mRNA (240 pg gRNA and 300 pg mRNA per embryo). Stacked barplots show the percentage of albino-like/golden-like/class III (white), severe/class II (light grey), mild/class I (dark grey), and phenotypically wild-type (WT; black) embryos 48 hpf after injection. The total number of injected embryos (n) is shown below. The results were obtained from at least two independent experiments.

Figure 3. SpG and SpRY are efficient nucleases at minimal PAM targets *C. elegans*

a. Diagram illustrating one crRNA with NGH PAM (blue) and three crRNAs with NAN PAM (green) targeting wrmScarlet in *C. elegans*. The sequences of the crRNAs and PAMs are shown below.

b. Titration of SpG RNP concentration in *C. elegans*. Three distinct concentrations of SpG RNP, with the anti-wrmScarlet NGH guide 1, were tested in a strain expressing the *gtbp-1::wrmscarlet* reporter (CER541). Editing efficiency is defined as the number of F_1 worms exhibiting loss of fluorescence in the F_2 divided by the total number of separated *dpy-10* co-edited F_1 s. Each dot represents the editing efficiency in each individual P_0 that produced at least ten Dpy or Rol F_1 s. All three conditions were carried out in parallel injections. $p<0.05$ *, $p<0.0001$ **** (One-way ANOVA followed by Tukey's test for multiple comparisons)

c. Comparison of editing efficiencies with anti-wrmScarlet NGH guide 1 between (SpCas9) WT and SpG, and SpG and SpRY in independent experiments at an RNP concentration of 8.0 μ M. Editing efficiency, dots, and numbers are defined as in panel **b**. Conditions belonging to parallel injections are separated by a dashed line. ns: no significant difference, $p<0.0001$ **** (Student's *t*-test)

d. *In vitro* analysis of three anti-wrmScarlet NAN gRNAs. Different RNP combinations comprised of each guide and SpCas9 (WT), SpG, or SpRY were tested *in vitro* at 37 °C by incubating the RNPs with wrmScarlet PCR product for one hour. The top row of bands shows uncleaved PCR product at 693 bp and the specific cleavage products for each guide are specified in the figure. The gRNA appears as a faint band at approximately 100 bp.

e. *In vivo* analysis of the three anti-wrmScarlet NAN gRNAs. A titration of three distinct SpRY RNP concentrations were performed for guides 1 and 3 while guide 2 was tested at 8.0 μ M only. Additionally, the editing efficiency of wtSpCas9 in NAN sites was evaluated using guides 2 and 3. Editing efficiency, dots, and numbers are defined as in panel **b**. Conditions belonging to parallel injections are separated by a dashed line. ns: no significant difference, $p<0.01$ **, $p<0.0001$ **** (One-way ANOVA followed by Tukey's test for multiple comparisons [NAN 1 and 3], Student's *t*-test [NAN 2])

Figure 4. Further SpG and SpRY optimization *in vivo*

a. Prediction of gRNA activity *in vivo* using CRISPRscan. Stacked barplots show the percentage of highly efficient gRNAs (blue) and not highly efficient gRNAs (orange) in two groups separated based on CRISPRscan scores (>66 and ≤ 66). Highly efficient gRNAs generate more than 50% embryos with albino-like/golden-like/class III or severe/class II phenotypes and less than 10% phenotypically wild-type. Fisher test $p<0.05$ *

b. RNP can enhance SpG and SpRY activity in zebrafish. Stacked barplots show the percentage of albino-like/golden-like/class III (white), severe/class II (light grey), mild/class I (dark grey), and phenotypically wild-type (WT; black) embryos 48 h post fertilization (hpf) after injection. The total number of injected embryos (n) is shown below. The results were obtained from at least two independent experiments. mSpG and mSpRY injections data from **Fig. 2b,f**, and RNP injections data from **Supplementary Fig. 8**. The Fisher test p-value per comparison is shown.

c. Utility of SpG for the generation of the *swn-4*/SMARCA4 [R350C] substitution. Nucleotide substitutions corresponding to the amino acid change are underlined and PAMs for each nuclease are indicated in bold.

d. Utility of SpG and SpRY for the insertion of DNA sequences via HDR. By nested CRISPR¹⁸, the *usp-48*, *trx-1*, and *cep-1* genes were tagged endogenously with wrmScarlet at their C-terminus while a GFP::H2B transcriptional reporter was generated for W05H9.1. In the case of *usp-48* and *trx-1* which required a single cut near the stop codon (underlined), SpG-targetable NGH PAMs (blue) were selected. In the case of W05H9.1, an SpG-targetable NGH PAM (blue) was chosen near the start codon (underlined). In the case of *cep-1*, an SpRY-targetable NAN PAM (green) was at the stop codon (underlined). /: cut site, +: sense orientation, -: antisense orientation

e. EG9615 and CER660 worms which express SpCas9 and SpG endogenously in the germline (SpCas9e and SpGe), respectively, were injected with tracrRNA and a crRNA targeting *dpy-10* with an NGH PAM. The fluorescent markers *myo-2p::mCherry* and *myo-3p::mCherry* were used as co-injection markers. F₁ worms expressing mCherry in the pharynx or body wall muscle were singled out and the appearance of Dpy progeny was screened in the F₂. Editing efficiency is defined as the number of F₁ worms that segregate Dpy progeny in the F₂ divided by the total number of separated F₁s. Each dot represents the editing efficiency in each individual P₀ that produced at least ten mCherry-expressing F₁s. All conditions were carried out in parallel injections. p<0.05 * (One-way ANOVA followed by Tukey's test for multiple comparisons).






Figure 2. Vicencio, Sanchez-Bolaños, et al.


a




b




c




d




e





f




a



b



d



e






Figure 4. **Vicencio, Sanchez-Bolanos, et al.**

a




b



c



swn-4[R350C]/SMARCA4



d



NGH

Orientation

SpG	<i>usp-48</i> C-ter:	CTC GCT CAT/ TGAT ATT	-
	<i>trx-1</i> C-ter:	CTGCT TCA ATG/ ATCT T	-
	W05H9.1 N-ter:	TTTTA/ GAAT TGAGA	+
	<i>cep-1</i> C-ter:	CA/AAG TAA AATC	+

e

